281 related articles for article (PubMed ID: 2473661)
1. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.
Smoller BR; McNutt NS; Hsu A
Am J Surg Pathol; 1989 Aug; 13(8):680-4. PubMed ID: 2473661
[TBL] [Abstract][Full Text] [Related]
2. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups.
Ahmed I; Piepkorn M; Goldgar DE; Cannon-Albright LA; Meyer LJ; Skolnick MH; Zone JJ
J Cutan Pathol; 1991 Aug; 18(4):257-60. PubMed ID: 1939784
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
4. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
5. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research.
Smith KJ; Skelton HG; Heimer W; Baxter D; Angritt P; Frisman D; Wagner KF
J Am Acad Dermatol; 1993 Oct; 29(4):539-44. PubMed ID: 7691905
[TBL] [Abstract][Full Text] [Related]
6. Melanocytic lesions in a private pathology practice. Comparison of histologic features in different tumor types with particular reference to dysplastic nevi.
Hastrup N; Hou-Jensen K
APMIS; 1993 Nov; 101(11):845-50. PubMed ID: 8286092
[TBL] [Abstract][Full Text] [Related]
7. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.
Skelton HG; Smith KJ; Barrett TL; Lupton GP; Graham JH
Am J Dermatopathol; 1991 Dec; 13(6):543-50. PubMed ID: 1725245
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
9. The histological spectrum of acquired nevi. An analysis of the intraepidermal melanocytic proliferation in common and dysplastic nevi.
Urso C; Bondi R
Pathol Res Pract; 1994 Jun; 190(6):609-14. PubMed ID: 7984520
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
11. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
Cockerell CJ; Berson DS
Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
[TBL] [Abstract][Full Text] [Related]
12. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
13. Actin-binding protein expression in benign and malignant melanocytic proliferations.
Bouffard D; Duncan LM; Howard CA; Mihm MC; Byers HR
Hum Pathol; 1994 Jul; 25(7):709-14. PubMed ID: 8026830
[TBL] [Abstract][Full Text] [Related]
14. Increased epidermal growth factor receptors in melanocytic lesions.
Ellis DL; King LE; Nanney LB
J Am Acad Dermatol; 1992 Oct; 27(4):539-46. PubMed ID: 1383295
[TBL] [Abstract][Full Text] [Related]
15. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
Melamed RD; Aydin IT; Rajan GS; Phelps R; Silvers DN; Emmett KJ; Brunner G; Rabadan R; Celebi JT
J Invest Dermatol; 2017 Apr; 137(4):905-909. PubMed ID: 27890785
[TBL] [Abstract][Full Text] [Related]
16. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology.
Rhodes AR; Mihm MC; Weinstock MA
Mod Pathol; 1989 Jul; 2(4):306-19. PubMed ID: 2762287
[TBL] [Abstract][Full Text] [Related]
17. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas.
Spałkowska M; Dyduch G; Broniatowska E; Damiani G; Wojas-Pelc A
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833446
[No Abstract] [Full Text] [Related]
18. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
19. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
20. Cell kinetics of melanocytes in common and dysplastic nevi and in primary and metastatic cutaneous melanoma.
Urso C; Bondi R; Balzi M; Scubla E; Mauri P; Becciolini A; Tarocchi S; Vallecchi C
Pathol Res Pract; 1992 Apr; 188(3):323-9. PubMed ID: 1625997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
